This composite of clinical photographs displays gross anatomical specimens of rat lungs across four experimental groups at 8-week and 10-week intervals. The images illustrate a comparative study on Lipopolysaccharide (LPS)-induced pulmonary injury and the therapeutic effects of Thymoquinone-loaded PLGA nanoparticles (TQ-PLGA NPs). The 'Control' group shows normal pink, spongy pulmonary morphology. The 'TQ-PLGA' group exhibits mild apical hepatization (indicated by arrows). The 'LPS' group demonstrates significant pathology, including dark red consolidations, depressed areas, and contracted, small-sized lobules indicative of chronic pneumonia and tissue damage. In contrast, the 'LPS + TQ-PLGA' group shows visual evidence of restoration, characterized by a return to more normal lobule size and a mixed whitish-red color, though persistent small red foci (arrows) remain visible. These specimens highlight the progression of inflammatory lung disease and the macroscopic indicators of pharmacological intervention and tissue recovery in an animal model of chronic active pneumonia.

This composite of clinical photographs illustrates the macroscopic pathology of interstitial pneumonia, contrasting acute and chronic stages through gross specimens. Panels A and C represent the acute phase, showing lungs that fail to collapse and exhibit prominent rib impressions on the pleural surface. The parenchyma is characterized by diffuse hyperemia, giving it a dark red, mottled appearance, and interstitial edema within the perilobular connective tissue, which increases the overall firmness and weight of the organ. Panels B and D demonstrate the chronic stage of the disease. In this phase, the lungs remain non-collapsed with persisting rib impressions, but the color shifts to a pale, whitish-grey hue. This chromatic change reflects the progression to interstitial fibrosis and a further increase in tissue consistency. The specimens lack significant airway exudate, a hallmark distinguishing interstitial pneumonia from bronchopneumonia. This visual resource is intended for medical education in pathology and pulmonology to aid in identifying the gross morphological markers of lung injury progression from acute inflammation to chronic fibrotic remodeling.

This grayscale lung ultrasound image (transverse intercostal scan) illustrates key diagnostic features of bacterial lobar pneumonia. A significant area of subpleural consolidation is visible, demonstrating 'hepatization' where the lung tissue exhibits a tissue-like, hypoechoic echogenicity similar to liver parenchyma. Within this consolidated region, several small, hypoechoic tubular structures are identified by blue arrows, representing fluid bronchograms (fluid-filled bronchi). Superior to the consolidated lung, a hypoechoic to anechoic space marked by an asterisk (*) indicates a fibrinous inflammatory reactive pleural effusion. The visceral and parietal pleurae are separated by this fluid collection, which contains fine internal echoes suggestive of fibrin or debris. This image is an educational example of point-of-care ultrasound (POCUS) findings in pediatric pulmonary infection, highlighting the loss of normal lung aeration and the development of secondary pleural complications.

This diagnostic axial CT scan of the thorax, using a lung window, demonstrates classic features of lobar pneumonia. The primary finding is a large, dense area of consolidation localized to the lower lobe of the right lung. This consolidated region presents as a homogenous soft-tissue density that obscures the normal lung parenchyma and vascular markings, characteristic of alveolar fluid or exudate accumulation (pathologically corresponding to the stage of gray hepatization). In contrast, the left lung appears normal, displaying clear aeration with well-defined branching vascular and bronchial structures. The mediastinal structures are centered, and no pleural effusions are immediately visible in this section. This image serves as a clinical example of pulmonary consolidation, highlighting the visual distinction between healthy air-filled lung tissue and pathological density caused by an infectious process like lobar pneumonia.

This pathophysiology diagram illustrates the type-2 inflammation pathway in atopic dermatitis and urticaria, highlighting the mechanism of action for various biologic drugs. The visual shows an epithelial barrier at the top, where allergens interact with a dendritic cell. This triggers a cascade involving T-helper cells (Th0 differentiating into Th1 or Th2). The Th2 cell releases cytokines IL-4, IL-5, and IL-13, which activate B cells (producing IgE), eosinophils (Eo), and mast cells (releasing histamine). Key therapeutic targets and their inhibitors are shown with red 'X' marks: Dupilumab blocks the IL-4/IL-13 pathway; Lebrikizumab and Tralokinumab target IL-13; Mepolizumab, Reslizumab, and Benralizumab inhibit the IL-5 pathway and eosinophil activation; Omalizumab and Ligelizumab block IgE; Nemolizumab targets the IL-31 receptor (associated with pruritus); and Tezepelumab and Etokimab act upstream by inhibiting TSLP and IL-33 respectively. The diagram effectively maps the transition from allergen exposure to clinical manifestations like inflammation and vascular changes, providing a comprehensive overview of biological treatments in pediatric dermatology and immunology.

A pathophysiology diagram illustrating the Type 2 (T2) inflammatory pathway in asthma and the specific targets of various monoclonal antibodies. The diagram shows an epithelial barrier at the top where allergens trigger an antigen-presenting cell, which subsequently interacts with a naive T cell (Th0). The differentiation pathway is shown leading to Th2 cells, which produce cytokines IL-4, IL-5, and IL-13. Therapeutic interventions are indicated by red 'X' marks: Dupilumab is shown inhibiting IL-4 and IL-13 signaling; Omalizumab blocks free IgE (depicted as Y-shaped molecules) before they bind to Mast cells; and Mepolizumab, Reslizumab, and Benralizumab target the IL-5 pathway to prevent eosinophil (Eo) activation. Downstream effects include B cell class switching to IgE production, eosinophil recruitment, and mast cell degranulation leading to histamine release and airway inflammation. This educational visual provides a mechanistic overview of biologics used in severe asthma management.

This pathophysiology diagram illustrates the inflammatory cascades of allergic and non-allergic asthma. The process is divided into two primary pathways stemming from the airway epithelium. The Allergic pathway (left, green) shows a Type 2 helper T cell (Th2) mediated response. Naive CD4+ T cells interact with dendritic cells to become Th2 cells, which release cytokines IL-4, IL-13 (activating B cells to produce IgE), IL-9 (stimulating mast cells to release TNF, leading to neutrophil recruitment), and IL-5 (promoting eosinophil activation). The Non-allergic pathway (right, pink) is triggered by epithelial-derived cytokines IL-33, IL-25, and TSLP, which activate Type 2 innate lymphoid cells (ILC2). These cells release IL-5 and IL-13, leading to eosinophilia. The diagram also highlights therapeutic targets, specifically anti-IgE agents like omalizumab and anti-IL agents such as mepolizumab and reslizumab, which inhibit the downstream recruitment of inflammatory cells like eosinophils and neutrophils.